BIOMAT Database Logo BIOMAT Database Logo

Conventional dose cytosine arabinoside in combination chemotherapy for acute myelogenous leukemia. 1987

T A Lister, and A Z Rohatiner, and R Bassan, and W Gregory, and L Willis, and M J Barnett, and J Waxman, and M A Richards, and T S Ganesan, and J Tucker

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D003561 Cytarabine A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472) Ara-C,Arabinofuranosylcytosine,Arabinosylcytosine,Cytosine Arabinoside,Aracytidine,Aracytine,Cytarabine Hydrochloride,Cytonal,Cytosar,Cytosar-U,beta-Ara C,Ara C,Arabinoside, Cytosine,Cytosar U,beta Ara C
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004317 Doxorubicin Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN. Adriamycin,Adriablastin,Adriablastine,Adriblastin,Adriblastina,Adriblastine,Adrimedac,DOXO-cell,Doxolem,Doxorubicin Hexal,Doxorubicin Hydrochloride,Doxorubicin NC,Doxorubicina Ferrer Farm,Doxorubicina Funk,Doxorubicina Tedec,Doxorubicine Baxter,Doxotec,Farmiblastina,Myocet,Onkodox,Ribodoxo,Rubex,Urokit Doxo-cell,DOXO cell,Hydrochloride, Doxorubicin,Urokit Doxo cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000971 Antineoplastic Combined Chemotherapy Protocols The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form. Anticancer Drug Combinations,Antineoplastic Agents, Combined,Antineoplastic Chemotherapy Protocols,Antineoplastic Drug Combinations,Cancer Chemotherapy Protocols,Chemotherapy Protocols, Antineoplastic,Drug Combinations, Antineoplastic,Antineoplastic Combined Chemotherapy Regimens,Combined Antineoplastic Agents,Agent, Combined Antineoplastic,Agents, Combined Antineoplastic,Anticancer Drug Combination,Antineoplastic Agent, Combined,Antineoplastic Chemotherapy Protocol,Antineoplastic Drug Combination,Cancer Chemotherapy Protocol,Chemotherapy Protocol, Antineoplastic,Chemotherapy Protocol, Cancer,Chemotherapy Protocols, Cancer,Combinations, Antineoplastic Drug,Combined Antineoplastic Agent,Drug Combination, Anticancer,Drug Combination, Antineoplastic,Drug Combinations, Anticancer,Protocol, Antineoplastic Chemotherapy,Protocol, Cancer Chemotherapy,Protocols, Antineoplastic Chemotherapy,Protocols, Cancer Chemotherapy
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor
D015470 Leukemia, Myeloid, Acute Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES. Leukemia, Myelogenous, Acute,Leukemia, Nonlymphocytic, Acute,Myeloid Leukemia, Acute,Nonlymphocytic Leukemia, Acute,ANLL,Acute Myelogenous Leukemia,Acute Myeloid Leukemia,Acute Myeloid Leukemia with Maturation,Acute Myeloid Leukemia without Maturation,Leukemia, Acute Myelogenous,Leukemia, Acute Myeloid,Leukemia, Myeloblastic, Acute,Leukemia, Myelocytic, Acute,Leukemia, Myeloid, Acute, M1,Leukemia, Myeloid, Acute, M2,Leukemia, Nonlymphoblastic, Acute,Myeloblastic Leukemia, Acute,Myelocytic Leukemia, Acute,Myelogenous Leukemia, Acute,Myeloid Leukemia, Acute, M1,Myeloid Leukemia, Acute, M2,Nonlymphoblastic Leukemia, Acute,Acute Myeloblastic Leukemia,Acute Myeloblastic Leukemias,Acute Myelocytic Leukemia,Acute Myelocytic Leukemias,Acute Myelogenous Leukemias,Acute Myeloid Leukemias,Acute Nonlymphoblastic Leukemia,Acute Nonlymphoblastic Leukemias,Acute Nonlymphocytic Leukemia,Acute Nonlymphocytic Leukemias,Leukemia, Acute Myeloblastic,Leukemia, Acute Myelocytic,Leukemia, Acute Nonlymphoblastic,Leukemia, Acute Nonlymphocytic,Leukemias, Acute Myeloblastic,Leukemias, Acute Myelocytic,Leukemias, Acute Myelogenous,Leukemias, Acute Myeloid,Leukemias, Acute Nonlymphoblastic,Leukemias, Acute Nonlymphocytic,Myeloblastic Leukemias, Acute,Myelocytic Leukemias, Acute,Myelogenous Leukemias, Acute,Myeloid Leukemias, Acute,Nonlymphoblastic Leukemias, Acute,Nonlymphocytic Leukemias, Acute

Related Publications

T A Lister, and A Z Rohatiner, and R Bassan, and W Gregory, and L Willis, and M J Barnett, and J Waxman, and M A Richards, and T S Ganesan, and J Tucker
Mitoxantrone and high-dose cytosine arabinoside in refractory acute myelogenous leukemia.
August 1988, Cancer,
T A Lister, and A Z Rohatiner, and R Bassan, and W Gregory, and L Willis, and M J Barnett, and J Waxman, and M A Richards, and T S Ganesan, and J Tucker
Daunorubicin, cytosine arabinoside, 6-mercaptopurine riboside, and prednisolone (DCMP) combination chemotherapy for acute myelogenous leukemia in adults.
December 1975, Cancer,
T A Lister, and A Z Rohatiner, and R Bassan, and W Gregory, and L Willis, and M J Barnett, and J Waxman, and M A Richards, and T S Ganesan, and J Tucker
[Continuous infusion therapy with low dose cytosine arabinoside and etoposide in acute myelogenous leukemia patients hardly tolerable for intensive combination chemotherapy].
July 1995, [Rinsho ketsueki] The Japanese journal of clinical hematology,
T A Lister, and A Z Rohatiner, and R Bassan, and W Gregory, and L Willis, and M J Barnett, and J Waxman, and M A Richards, and T S Ganesan, and J Tucker
Combination amsacrine and high-dose cytosine arabinoside in acute leukemia.
January 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
T A Lister, and A Z Rohatiner, and R Bassan, and W Gregory, and L Willis, and M J Barnett, and J Waxman, and M A Richards, and T S Ganesan, and J Tucker
[Combination of AMSA-high dose cytosine arabinoside in acute leukemia].
June 1985, Presse medicale (Paris, France : 1983),
T A Lister, and A Z Rohatiner, and R Bassan, and W Gregory, and L Willis, and M J Barnett, and J Waxman, and M A Richards, and T S Ganesan, and J Tucker
Low-dose cytosine arabinoside in the myelodysplastic syndromes and acute myelogenous leukemia.
September 1985, Cancer,
T A Lister, and A Z Rohatiner, and R Bassan, and W Gregory, and L Willis, and M J Barnett, and J Waxman, and M A Richards, and T S Ganesan, and J Tucker
Low dose cytosine arabinoside in myelodysplasia and acute myelogenous leukemia: a review.
August 1987, Leukemia,
T A Lister, and A Z Rohatiner, and R Bassan, and W Gregory, and L Willis, and M J Barnett, and J Waxman, and M A Richards, and T S Ganesan, and J Tucker
[Mitoxantrone and conventional-dose cytosine arabinoside for relapsed and refractory acute leukemia].
May 1992, Gan to kagaku ryoho. Cancer & chemotherapy,
T A Lister, and A Z Rohatiner, and R Bassan, and W Gregory, and L Willis, and M J Barnett, and J Waxman, and M A Richards, and T S Ganesan, and J Tucker
[Chemotherapy of chronic myelogenous leukemia in blastic crisis--vindesine, cytosine arabinoside prednisolone combination therapy].
May 1984, Gan to kagaku ryoho. Cancer & chemotherapy,
T A Lister, and A Z Rohatiner, and R Bassan, and W Gregory, and L Willis, and M J Barnett, and J Waxman, and M A Richards, and T S Ganesan, and J Tucker
[Combination chemotherapy with cytosine arabinoside and daunomycin in childhood acute leukemia].
May 1973, [Rinsho ketsueki] The Japanese journal of clinical hematology,
Copied contents to your clipboard!